| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| S9083 |
Global fee urgent care centers |
33,391 |
29,646 |
$2.84M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
28,803 |
24,769 |
$1.31M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13,548 |
12,824 |
$842K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,512 |
12,106 |
$780K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
11,678 |
11,419 |
$666K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
18,062 |
15,711 |
$537K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
5,631 |
5,405 |
$457K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
9,851 |
8,113 |
$453K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
5,380 |
4,699 |
$233K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
23,065 |
20,713 |
$184K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,418 |
2,278 |
$105K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,698 |
3,477 |
$52K |
| M0240 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
263 |
253 |
$50K |
| 86328 |
|
877 |
867 |
$35K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
785 |
709 |
$22K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
705 |
657 |
$19K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
63 |
60 |
$11K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
768 |
695 |
$10K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
418 |
373 |
$8K |
| 36415 |
Collection of venous blood by venipuncture |
3,752 |
3,691 |
$7K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
37 |
31 |
$5K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
304 |
304 |
$4K |
| 90686 |
|
192 |
190 |
$4K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
19 |
19 |
$4K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
212 |
207 |
$2K |
| 87081 |
|
236 |
226 |
$2K |
| 99201 |
|
61 |
60 |
$1K |
| 87428 |
|
80 |
75 |
$808.39 |
| 0031A |
|
17 |
16 |
$640.00 |
| 0011A |
|
17 |
15 |
$560.00 |
| 73630 |
|
27 |
24 |
$358.32 |
| 81002 |
|
339 |
323 |
$284.34 |
| 71046 |
Radiologic examination, chest; 2 views |
13 |
13 |
$202.73 |
| 73110 |
|
12 |
12 |
$188.38 |
| 73130 |
|
13 |
13 |
$110.54 |
| 99000 |
|
216 |
213 |
$78.00 |
| 96127 |
|
16 |
16 |
$38.56 |
| 99051 |
|
195 |
185 |
$28.00 |
| 81003 |
|
167 |
134 |
$11.20 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
17 |
17 |
$0.01 |
| 3008F |
|
6,174 |
4,759 |
$0.00 |
| 3074F |
|
1,604 |
1,248 |
$0.00 |
| 3075F |
|
116 |
102 |
$0.00 |
| 3079F |
|
534 |
437 |
$0.00 |
| 3080F |
|
39 |
28 |
$0.00 |
| 1160F |
|
130 |
129 |
$0.00 |